

## INFORMATION ONLY

### Updated Share Splits for Intravenous Immunoglobulins

Customer Letter # 2021-20

2021-03-18

Dear Colleagues

In Customer Letter (CL) [2020-50](#), hospital customers were asked to be agile and responsive to immunoglobulin (Ig) brand changes and fluctuations, particularly for intravenous Ig (IVIg). Canadian Blood Services is committed to supporting hospital customers in managing their IVIg supply by sharing new information in a timely manner.

We are following up on CL [2021-03](#) to notify hospital customers that we have been informed by CSL Behring that our supply of Privigen® is being reduced, and our next new shipment will be received in August 2021. Projected depletion dates for each vial size are unchanged from those provided in CL 2021-03.

Table 1 outlines the previous and updated projected national share splits for IVIg. Specifically, the updated volumes of Privigen® that will result in a reduction in our target share splits from 16% to 12%. Hospitals are receiving regular reports showing their IVIg brand share splits and the target share splits. This should allow hospitals to monitor their progress toward the target and take appropriate action. As a reminder, Octagam® is now available to order (refer to CL [2021-14](#) for more details).

**Table 1: National Share Splits for IVIg**


Product	Previously Projected Share Split	Updated Projected 2021-2022 Share Split
Gammagard Liquid®	26%	29%
IGIVnex®/Gamunex®	44%	45%
Privigen®	16%	12%
Panzyga®	6%	5%
Octagam®	8%	9%

Importantly, although the mix of products is being adjusted, we continue to maintain sufficient supply of IVIg. We sincerely appreciate your continued support as we navigate these changes by working collaboratively.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at [www.blood.ca](http://www.blood.ca) in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,



Sylvain Grenier,  
Director, Plasma Protein and Related Products Formulary Program